Chronic lymphocytic leukaemia

2010 ◽  
pp. 4240-4247
Author(s):  
Clive S. Zent ◽  
Aaron Polliack
Keyword(s):  
North America ◽  
Chronic Lymphocytic Leukaemia ◽  
B Lymphocyte ◽  
Lymphocytic Leukaemia ◽  
Immunoglobulin Gene ◽  
Cell Of Origin ◽  
Small Lymphocytic Lymphoma ◽  
Lymphoid Neoplasm ◽  
Surface Immunoglobulin

Chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL) is the most prevalent lymphoid neoplasm in Europe and North America. The ‘cell of origin’ is a mature B lymphocyte that has a rearranged immunoglobulin gene. CLL cells express modest amounts of surface immunoglobulin, and are characterized by defective apoptosis. The cause of CLL is unknown....

Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia

2005 ◽  
Vol 129 (4) ◽  
pp. 499-510 ◽  
Author(s):  
Katja Mauerer ◽  
David Zahrieh ◽  
Gullu Gorgun ◽  
Aihong Li ◽  
Jianbiao Zhou ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Gene Segment ◽  
Immunoglobulin Gene

Cyclin D1 overexpression in proliferation centres of small lymphocytic lymphoma/chronic lymphocytic leukaemia

2017 ◽  
Vol 70 (10) ◽  
pp. 899-902 ◽  
Author(s):  
Larissa Sena Teixeira Mendes ◽  
Natalie Peters ◽  
Ayoma D Attygalle ◽  
Andrew Wotherspoon
Keyword(s):  
Chronic Lymphocytic Leukaemia ◽  
Cyclin D1 ◽  
Lymphocytic Leukaemia ◽  
Small Lymphocytic Lymphoma

scholarly journals Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma

2018 ◽  
Vol 185 (2) ◽  
pp. 347-350 ◽  
Author(s):  
Sikander Ailawadhi ◽  
Bhagirathbhai R. Dholaria ◽  
Sharad Khurana ◽  
Taimur Sher ◽  
Victoria Alegria ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Chronic Lymphocytic Leukaemia ◽  
Lymphocytic Leukaemia ◽  
Small Lymphocytic Lymphoma

Chronic lymphocytic leukaemia

2020 ◽  
pp. 5302-5310
Author(s):  
Clive S. Zent ◽  
Aaron Polliack
Keyword(s):  
Bone Marrow ◽  
Chronic Lymphocytic Leukaemia ◽  
B Cell ◽  
Peripheral Blood ◽  
B Lymphocyte ◽  
Lymphocytic Leukaemia ◽  
Bone Marrow Failure ◽  
Curative Therapy ◽  
Symptomatic Disease ◽  
Autoimmune Cytopenias

Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma is the most prevalent lymphoid neoplasm in Europe and North America. The ‘cell of origin’ is a mature B lymphocyte with a rearranged immunoglobulin gene. CLL cells express modest amounts of surface immunoglobulin, and are characterized by defective apoptosis. The cause of CLL is unknown. Most patients show no specific clinical features of disease and are diagnosed during evaluation of an incidental finding of peripheral blood lymphocytosis, lymphadenopathy, or splenomegaly. A small percentage of patients (<10%) present with symptomatic disease resulting from (1) tissue accumulation of lymphocytes such as disfiguring lymphadenopathy, splenomegaly with abdominal discomfort, profound fatigue, drenching night sweats, weight loss, and fever; or (2) manifestations of marrow failure with cytopenias including anaemia and thrombocytopenia. All CLL patients have an increased risk of infection, autoimmune cytopenias, and second haematological (e.g. diffuse large B-cell lymphoma) and nonhaematological malignancies. Diagnosis is usually made by analysis of the immunophenotype of the monoclonal circulating cells in the peripheral blood. In patients with the small lymphocytic variant of CLL without a detectable circulating monoclonal B-cell population, the diagnosis is made using tissue from the bone marrow, lymph nodes, or spleen. Treatment—there is no standard curative therapy and patients should not be treated until they have progressive and symptomatic disease or develop anaemia or thrombocytopenia due to bone marrow failure. If a decision is made to treat, then the best initial treatment should be given, based on evaluation of the patient’s disease characteristics with specific attention to the integrity of TP53 (coding for p53) and patient fitness.

scholarly journals Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases

2019 ◽  
Vol 12 (2) ◽  
pp. 69 ◽  
Author(s):  
Daniel A. Rodrigues ◽  
Fernanda S. Sagrillo ◽  
Carlos A. M. Fraga
Keyword(s):  
Clinical Trials ◽  
Follicular Lymphoma ◽  
Chronic Lymphocytic Leukaemia ◽  
Drug Administration ◽  
Small Molecule ◽  
Lymphocytic Leukaemia ◽  
Food And Drug Administration ◽  
Small Lymphocytic Lymphoma ◽  
Dual Inhibitor ◽  
Systemic Therapies

Duvelisib (Copiktra®) is a dual inhibitor of phosphoinositide 3-kinases (PI3Kδ and PI3Kγ). In 2018, duvelisib was first approved by the Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) after at least two prior therapies. Duvelisib has also been approved under accelerated track for relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. In this review, we provide a series of information about duvelisib, such as the development of clinical trials for LLC/SLL and FL and the steps used for its synthesis.

Sign in / Sign up

Export Citation Format

Share Document